CXCR4 and acute myeloid leukemia: Consequently, a CXCR4-directed ERT approach in earlier therapy lines may not only enhance objective outcomes but also improve the quality of life for high-risk AML patients, as it counteracts the decline associated with multiple treatment lines and their long-term toxicities 45.